Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics

Table 2 The risk of hepatitis B virus reactivation in patients with interleukin-17 inhibitors

Ref.	Number of HBV patients	HBV status	Disease	Drugs	Prophylaxis	Follow-up	HBV reactivation
Chiu et al[52], 2018	49	(1) 25 CHB; and (2) 24 resolved HBV. HBV-DNA at baseline (-) in 11 patients with resolved HBV	Psoriasis	Secukinumab	Yes: 3 patients with CHB	3 mo	(1) 6 patients with CHB without prophylaxis. (no hepatitis); and (2) 1 patient with resolved HBV with positive viral load at baseline (no hepatitis)
Moneva-Leniz et al[72], 2020	4	(1) 2 CHB; and (2) 2 resolved HBV. HBV-DNA at baseline (-)	Psoriasis/palmoplantar psoriasis	Secukinumab	Yes: 1 patient with CHB and 1 patient with resolved HBV	20 mo	(1) 0; and (2) 0
Feaster et al[73], 2018	1	A carrier of congenital HBV infection1	Psoriasis and PsA	Secukinumab	No	24 mo	0
Bevans et al[74], 2018	1	Seropositive hepatitis1	Palmoplantar psoriasis and AS	Secukinumab	No	14 mo	0
Yanagihara et al[75], 2017	1	CHB	Psoriasis vulgaris	Secukinumab	Yes	9 mo	0
Peccerillo et al[76], 2018	1	Resolved HBV. HBV-DNA at baseline (-)	Psoriasis	Secukinumab	Yes	14 mo	0
Koike et al[53], 2019	1	CHB	Psoriasis and PsA	Ixekizumab	Yes	18 mo	0
Lora et al[54], 2019	1	Resolved HBV. HBV-DNA at baseline (-)	Psoriasis	Ixekizumab	Yes	12 mo	0

¹A diagnosis in an article was used due to lack of data regarding hepatitis B virus (HBV) serology and viral load. If a study included both of patients with chronic HBV and those with resolved HBV, we labeled the former with (1) and the latter with (2) in the column with HBV status. HBV: Hepatitis B virus; AS: Ankylosing spondylitis; CHB: Chronic HBV; PsA: Psoriatic arthritis.